Livzon Pharmaceutical
Livzon Pharmaceutical Group Inc., commonly referred to as Livzon, is a prominent player in the pharmaceutical industry, headquartered in China (CN). Founded in 1992, the company has established a strong presence in various operational regions, focusing on the development, manufacturing, and marketing of innovative pharmaceutical products. Specialising in areas such as biopharmaceuticals, traditional Chinese medicine, and chemical pharmaceuticals, Livzon is recognised for its commitment to quality and research-driven solutions. The company’s core offerings include a range of therapeutic agents, particularly in the fields of oncology and infectious diseases, which distinguish it in a competitive market. With a robust market position, Livzon has achieved significant milestones, including numerous product approvals and collaborations that enhance its global footprint. The company continues to advance its mission of improving health outcomes through innovative therapies and a dedication to excellence in pharmaceutical development.
DitchCarbon Score
How does Livzon Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Livzon Pharmaceutical's score of 27 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Livzon Pharmaceutical's reported carbon emissions
In 2023, Livzon Pharmaceutical, headquartered in China (CN), reported total carbon emissions of approximately 514,332,930 kg CO2e. This figure includes 155,807,280 kg CO2e from Scope 1 emissions and 358,525,650 kg CO2e from Scope 2 emissions. Over the past few years, the company has shown a trend of decreasing emissions, with a total of about 565,660,000 kg CO2e in 2022 and 535,831,500 kg CO2e in 2021. Despite these reductions, Livzon Pharmaceutical has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company continues to monitor its emissions, focusing on improving its operational efficiency and reducing its carbon footprint. As the pharmaceutical industry increasingly prioritises sustainability, Livzon's commitment to tracking and reporting its emissions is crucial for aligning with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 30,427,800 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 543,952,500 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Livzon Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
